-+ 0.00%
-+ 0.00%
-+ 0.00%
Trupanion (TRUP) Could Be 25% Below Fair Value If Its Growth Narrative Holds
Share
Listen to the news

Trupanion stock reaction and recent performance

Trupanion (TRUP) has drawn fresh attention after a recent share price move, with the stock closing at $27.88 on 27 August 2026. The move comes alongside contrasting short and longer term return patterns.

Over the past day the stock declined 4.36%, and over the past week it fell 12.44%. That shorter term weakness sits against a gain of 13.84% over the past month and a 29.92% rise over the past 3 months, while the 1 year return is down 38.32%.

For investors watching Trupanion, the picture is mixed, with recent share price gains over the past few months set against a weaker year-to-date share price return and a steep 1 year total shareholder return decline of 38.32%.

The recent pullback from short term highs around US$27.88 suggests some investors may be reassessing risk after the strong 90 day share price return of 29.92%. This is especially relevant given the longer term total shareholder return over 5 years is down 67.02%. That combination often reflects changing views on how sustainable the current business performance and valuation might be, rather than a simple shift driven by a single event.

Spot fresh momentum in pet and insurance stocks like Trupanion by scanning a hand picked 19 high quality undiscovered gems that share strong fundamentals yet still fly under most investors’ radar.

For Trupanion, the recent swing raises a simple tension. Are investors re-rating the business after fresh revenue and profit growth, or are they just rotating in and out after a sharp three-month rebound? The valuation numbers give clearer clues in the next section.

Most Popular Narrative: 25.2% Undervalued

Trupanion’s most followed narrative points to a fair value of $37.25 versus the last close at $27.88, so the gap between price and narrative valuation is sizeable and worth unpacking.

Improved underwriting discipline, focus on higher lifetime value pets, and optimization of acquisition channels are driving higher-quality book growth and supporting strong free cash flow, setting up for scalable and more profitable expansion in coming years.

Read the complete narrative.

Curious what turns that underwriting story into a higher fair value for Trupanion? The narrative leans heavily on projected revenue growth, margin uplift, and a premium future earnings multiple. The mix of those three inputs drives the $37.25 figure and the implied upside.

Result: Fair Value of $37.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Trupanion narrative also leans on subscriber growth and stable margins, so weaker pet additions or renewed veterinary cost pressure could quickly challenge those assumptions.

Find out about the key risks to this Trupanion narrative.

Another View On Trupanion’s Valuation

The fair value narrative for Trupanion points to upside, but the current P/E of 52.7x sends a different signal. It is much higher than both the US Insurance industry average of 11.2x and the peer average of 12.3x, and also well above the fair ratio of 14.3x that the market could move towards. That gap suggests meaningful valuation risk if growth or margins fall short of expectations. The question is how much premium you are comfortable paying for this earnings profile.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:TRUP P/E Ratio as at Sep 2026
NasdaqGM:TRUP P/E Ratio as at Sep 2026

Next Steps

Does the mixed message on Trupanion’s valuation and recent share price swings leave you unsure which side to lean toward? Move quickly to review the key positives and pressure test them against your own expectations by checking the 3 key rewards.

Looking for more Trupanion style investment ideas?

Do not just stop at Trupanion. Broaden your watchlist with a few focused stock ideas that match different risk and income preferences using the Simply Wall Street Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending